Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer

Inclusion Criteria: * Participants must have one of the following: a) Histological or cytological diagnosis of high-grade serous ovarian, fallopian, or peritoneal cancer, stage III or IV; b) In the opinion of investigator, highly suspicious stage III or IV ovarian, fallopian, or peritoneal cancer (histologically confirmed non-serous ovarian, fallopian, and peritoneal cancers will be considered screening failures). * At least one biopsiable lesion by CT/US or laparoscopy. * Have not received previous treatment for ovarian cancer. * Life expectancy of greater than 6 months. * Eastern Cooperative Oncology Group (ECOG) performance status \<3 (Karnofsky \>60%). * Must have adequate organ and marrow function. * Deemed eligible for neo-adjuvant chemotherapy with carboplatin and paclitaxel and surgery by their oncologist. * Women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Active second malignancy within last 2 years (except non-melanoma skin cancer or in situ carcinomas. * Prior treatment for ovarian cancer. * Potential participants with known brain metastases will be excluded from this clinical trial. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin and paclitaxel. * Known allergy to carboplatin, paclitaxel, or cremophor. * Uncontrolled concomitant illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Women who are pregnant. Breastfeeding should be discontinued if the mother is treated with carboplatin and paclitaxel. These potential risks may also apply to other agents used in this study. * HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with carboplatin and paclitaxel or other agents administered during the study.